CXCheng Xu

Cheng Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Cheng Xu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Cong Wang

    Department of Pathology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China

    1 shared publication
  • Jing Wu

    Department of Pathology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China

    1 shared publication
  • Ying Ding

    Department of Pathology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu Province, China

    1 shared publication
  • Zhihong Zhang

    Department of Pathology, The First Affiliated Hospital With Nanjing Medical University, No. 300 of Guangzhou Road, Nanjing, Jiangsu Province, China.

    1 shared publication

Latest Publications

  • Primary mucinous cystadenocarcinoma of the breast commonly harbours TP53 mutations and PI3K/AKT pathway alterations

    by Cheng Xu, Jing Wu, Ying Ding, Zhihong Zhang, Cong Wang

    Primary mucinous cystadenocarcinoma (MCA) of the breast is an invasive breast carcinoma characterized by cystic structures lined by tall columnar cells with abundant intracytoplasmic mucin, resembling pancreatobiliary or ovarian mucinous cystadenocarcinoma. Fewer than 50 cases have been reported worldwide so far. In this series, we describe the clinical, morphologic, immunohistochemical, and molecular features of 5 cases of breast MCA. The median age of the patients was 54 years (range: 53 to 64 years) and invasive size was 2 mm to 30 mm (our study reported the smallest invasive size to date in case 5). DCIS was present in 4 of 5 cases. Despite the prevailing view that breast MCA may be indolent, our cases exhibit robust growth, characterized by a relatively high Ki67 index, brisk mitosis, and 1 case of micrometastasis of axillary lymph node micrometastasis. Moreover, we conducted large panel sequencing on 4 cases, and emphasize their molecular essence; that is, breast MCA exhibits a high frequency of TP53 mutations and PI3K/AKT pathway alterations. A review of the literature on previous and current genomic profiles indicates that MCAs are similar to triple-negative breast cancer (TNBC). In our opinion, patients with breast MCA should receive precise clinical treatment similarly to invasive breast carcinoma of no special type, with careful consideration of tumor grade, stage, immunophenotype, and genomic profile, and we believe that PI3K-targeted therapies may play a valuable role in treating this rare tumor.